Glycyrrhizinate Monoammonium Cysteine-Loaded Lipid Nanoparticles Allow for Improved Acute Liver Injury Therapy by Yunjie Xu, Pinghui Li, Shiran Sun, Yulin Chen, Lixia Feng, Dawei Jiang, Chidan Wan, Jianbo Li, Xiong Cai

“…This study contributes valuable insights into the utilization of LNPs in liver disease treatment, presenting a promising direction for future clinical applications.…”
Get full text

Characteristics of NAFLD Based on Hypopituitarism by Kazuhisa Kodama, Atsuhiro Ichihara, Yasufumi Seki, Yuichi Ikarashi, Takaomi Sagawa, Tomomi Kogiso, Maiko Taniai, Katsutoshi Tokushige

“…Hypopituitarism and hypothalamic disorders, which induce central obesity and appetite disorder, are associated with nonalcoholic fatty liver disease (NAFLD). We retrospectively analyzed the clinical features of NAFLD patients with hypopituitarism. …”
Get full text

Prevalence and risk factors of hyperuricaemia in non-obese Chinese: a single-centre cross-sectional study by Chengfu Xu, Jinghua Wang, Xinyu Wang, Yishu Chen, Shenghui Chen, Haoliang Zhai

“…Participants with hyperuricaemia showed a higher prevalence of metabolic syndrome and fatty liver disease than participants with normouraemia. Age, waist circumference, estimated glomerular filtration rate, blood urea nitrogen, excessive drinking and fatty liver were associated with hyperuricaemia in both genders.Conclusion The prevalence of hyperuricaemia was 9.4% in non-obese Chinese adults. …”
Get full text

Long-term results of antiviral therapy in patients with chronic hepatitis C with sustained virologic response by T. M. Ignatova, T. N. Lopatkina, V. P. Chulanov, Ye. V. Gaydasheva, S. N. Batskikh, G. V. Mikhaylovskaya, D. T. Abdurakhmanov, S. Yu. Karpov, Ye. N. Nikulkina, O. A. Chernova

“…There were no cases of decompensation of LC, hepatocellular carcinoma and death due to liver disease.Conclusion. At patients who have achieved SVO as a result of AVT, late relapses of HCV-infection are rare and in the majority no disease progression was found. …”
Get full text

Noninvasive Evaluation of Liver Function in Morbidly Obese Patients by Patrick H. Alizai, Isabella Lurje, Andreas Kroh, Sophia Schmitz, Tom Luedde, Julia Andruszkow, Ulf P. Neumann, Florian Ulmer

“…More than half of the obese patients develop nonalcoholic fatty liver disease (NAFLD), which may further progress to nonalcoholic steatohepatitis (NASH) and cirrhosis. …”
Get full text

Association of non-selective β blockers with the development of renal dysfunction in liver cirrhosis: a systematic review and meta-analysis by Xiangbo Xu, Fangbo Gao, Ting Wang, Zuyao Yang, Qingchun Zhao, Xingshun Qi

“…Subgroup meta-analyses were performed according to the proportions of ascites and Child-Pugh class B/C and the mean model for end-stage liver disease (MELD) score. Quality of evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation framework.Results Fourteen studies were finally included. …”
Get full text

Ethanol extract of Polygonatum cyrtonema Hua mitigates non-alcoholic steatohepatitis in mice by Dongliang Chen, Yue Shen, Yue Shen, Fang Huang, Bo Huang, Shangfu Xu, Shangfu Xu, Lisheng Li, Lisheng Li, Jie Liu, Zheng Li, Xia Li

“…Modern pharmacological research has confirmed that Polygonum cyrtonema Hua is able to alleviate nonalcoholic fatty liver disease, but the precise mechanism requires further investigation. …”
Get full text

High fructose rewires gut glucose sensing via glucagon-like peptide 2 to impair metabolic regulation in mice by Eya Sellami, Paulo Henrique Evangelista-Silva, Caio Jordão Teixeira, Khoudia Diop, Patricia Mitchell, Fernando Forato Anhê

“…Objective: Increased fructose consumption contributes to type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD), but the mechanisms are ill-defined. …”
Get full text

Risk factors for hepatocellular carcinoma: an umbrella review of systematic review and meta-analysis by Jie Wang, Kaijie Qiu, Songsheng Zhou, Yichao Gan, Keting Jiang, Donghuan Wang, Haibiao Wang

“…Smoking, obesity, non-alcoholic fatty liver disease, diabetes, low platelet, elevated liver enzymes and liver fluke infection increase HCC risk, while coffee consumption, a healthy diet, and bariatric surgery lower it. …”
Get full text

Interface Hepatitis over Grade 2 May Differentiate Chronic Inflammation Associated with CHB from NAFLD in the Early Stage by Yong-fen Zhu, Jin Wang, Jia-zhui Fang, Qiao Yang, Fang-fang Lv

“…Patients with chronic hepatitis B (CHB) concomitant with nonalcoholic fatty liver disease (NAFLD) are increasing. Objectives. To identify pathological features that can be used to differentiate between chronic inflammation caused by CHB and that caused by NAFLD. …”
Get full text

e-GLR Score Predicts Early Graft Loss in Adult Live-Donor Liver Transplantation by Viniyendra Pamecha, MS, MRCS, FRCS, FEBS, Nilesh Sadashiv Patil, MS, MCh, Tharun Gattu, MS, Guresh Kumar, MSc, MPhil, PhD, Bramhadatta Pattnaik, MS, MCh, Nihar Mohapatra, MS, MCh, Gaurav Sindwani, MD, PDCC, Ashok Choudhury, MD, DM

“…Multivariate logistic regression analysis determined donor age (P = 0.045), estimated (e) graft weight (P = 0.001), and the model for end-stage liver disease (MELD) score (0.001) as independent predictors of early graft loss due to EGD. …”
Get full text

Unveiling the novel role of circadian rhythms in sepsis and septic shock: unexplored implications for chronotherapy by Stewart D. Ramsay, Stewart D. Ramsay, Stewart D. Ramsay, Marni A. Nenke, Marni A. Nenke, Emily J. Meyer, Emily J. Meyer, David J. Torpy, David J. Torpy, Richard L. Young, Richard L. Young, Richard L. Young, Richard L. Young

“…These disruptions misalign external cues to body processes and contribute to diseases such as obesity and non-alcoholic fatty liver disease. They also exacerbate pre-existing health issues, such as depression and inflammatory bowel disease. …”
Get full text

Joint Group and Multi Institutional Position Opinion: Cirrhotic Cardiomyopathy—From Fundamentals to Applied Tactics by Ivan Rankovic, Ivana Babic, Jelena Martinov Nestorov, Jelena Bogdanovic, Maja Stojanovic, Jovanka Trifunovic, Nikola Panic, Mihailo Bezmarevic, Jelena Jevtovic, Dusan Micic, Vladimir Dedovic, Nemanja Djuricic, Filip Pilipovic, Elena Curakova Ristovska, Tijana Glisic, Sanja Kostic, Nemanja Stojkovic, Nata Joksimovic, Mileva Bascarevic, Aleksandra Bozovic, Lewis Elvin, Ajibola Onifade, Keith Siau, Elizaveta Koriakovskaia, Vladimir Milivojevic

“…This is not only a review but also a comprehensive distillation of the insights from practicing clinical hepatologists and other specialties engaged in advanced approaches to treating liver disease and its sequelae.…”
Get full text

Chemical Characterization and Differential Lipid-Modulating Effects of Selected Plant Extracts from Côa Valley (Portugal) in a Cell Model for Liver Steatosis by Ricardo Amorim, Mário Pedro Marques, Catarina Melim, Carla Varela, Vilma A. Sardão, José Teixeira, Maria Inês Dias, Lillian Barros, Paulo J. Oliveira, Célia Cabral

“…Given their rich ethnomedicinal history, we evaluated their protective effects on an in vitro model of metabolic dysfunction-associated steatotic liver disease (MASLD). Methods: Decoction (D) and hydroalcoholic (EtOH80%) extracts were prepared and chemically characterized. …”
Get full text

Intravoxel Incoherent Motion (IVIM) Diffusion-Weighted Imaging (DWI) in Patients with Liver Dysfunction of Chronic Viral Hepatitis: Segmental Heterogeneity and Relationship with Ch... by Lei Ding, Lianxiang Xiao, Xiangtao Lin, Chunmei Xiong, Lingbo Lin, Shijun Chen

“…This was a retrospective study of 82 consecutive patients with chronic liver disease who underwent MRI examination at the Jinan Infectious Diseases Hospital between January 2015 and December 2016. …”
Get full text

Prevalence of Hepatitis C Virus Infection in a Surgical Population of Southeast China: A Large-Scale Multicenter Study by Ping Chen, Yang Zheng, Yubo Cai, Pengfei Zou, Nan Li, Conggao Peng, Hainv Gao, Jimin Liu, Yongping Chen, Zhaowei Tong, Lanjuan Li

“…Chronic HCV infection affects 80 million people globally and may progress to advanced liver disease. The present study aims to investigate the present epidemiology of HCV infection in a southeastern Chinese surgical patient cohort. …”
Get full text

Metformin and Probiotics Interplay in Amelioration of Ethanol-Induced Oxidative Stress and Inflammatory Response in an In Vitro and In Vivo Model of Hepatic Injury by Farhin Patel, Kirti Parwani, Dhara Patel, Palash Mandal

“…Despite rigorous research, there is still no Food and Drug Administration (FDA) approved therapies for any stage of alcoholic liver disease (ALD). Interestingly, metformin (Met) and several probiotic strains possess the potential of inhibiting alcoholic liver injury. …”
Get full text

Metallothionein 1B attenuates inflammation and hepatic steatosis in MASH by inhibiting the AKT/PI3K pathway by Canghai Guan, Xinlei Zou, Wujiang Shi, Jianjun Gao, Chengru Yang, Yifei Ge, Zhaoqiang Xu, Shaowu Bi, Xiangyu Zhong

“…Metabolic dysfunction–associated steatohepatitis (MASH) is a severe form of metabolic dysfunction–associated fatty liver disease metabolic dysfunction-associated steatohepatitis , characterized by hepatic steatosis, inflammation, and fibrosis. …”
Get full text

Statin prescriptions and progression of advanced fibrosis risk in primary care patients with MASLD by Andrew D Schreiner, William P Moran, Jingwen Zhang, Patrick D Mauldin, Justin Marsden, Mulugeta Gebregziabher, Chelsey A Petz, David G Koch, Chloe Bays

“…Objective We aimed to determine the association of statins with progression to a high risk for advanced fibrosis in primary care patients with metabolic dysfunction-associated steatotic liver disease (MASLD).Design This retrospective cohort study of electronic health record data included patients with MASLD and an initial low or indeterminate risk for advanced fibrosis, determined by Fibrosis-4 Index (FIB-4) score (<2.67). …”
Get full text

Duodenal Organoids From Metabolic Dysfunction-Associated Steatohepatitis Patients Exhibit Absorptive and Barrier Alterations by Alia Hadefi, Morgane Leprovots, Gilles Dinsart, Maryam Marefati, Marjorie Vermeersch, Daniel Monteyne, David Pérez-Morga, Anne Lefort, Frédérick Libert, Laurine Verset, Claire Liefferinckx, Christophe Moreno, Jacques Devière, Eric Trépo, Marie-Isabelle Garcia

“…Background and Aims: Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease that can lead to fibrosis, cirrhosis, and hepatocellular carcinoma. …”
Get full text